For professionals

The evidence, in full view.

How Ankaferd is proposed to work, every source we rely on, and the limits of that evidence, stated as plainly as the strengths.

Coagulation values
9
coagulation values reported normal during administration⁠1⁠2
Library
30
sources in the library, 29 with a DOI or PubMed link
Controlled trials
7
controlled or randomised trials listed, placed by their titles and not yet appraised by us
Red cells gathering in a protein network. Illustrative, not to scale. Library updated October 2026.

01 · Proposed mechanism

Three magnifications, one network.

Scroll to zoom from the wound surface to the red-cell membrane. Each view shows what published research reports, and the deepest view is a schematic of what is proposed⁠1.

The proposed mechanism, shown at three magnifications View one, tissue: drops of Ankaferd solution meet blood welling from a small wound, and a fine network is drawn across the blood surface. View two, cells: red blood cells gathered into clusters, with fine protein strands running between them. View three, molecules: the membranes of two neighbouring red cells, each lined on the inside with a lattice of spectrin, ankyrin and actin, and between them elongated fibrinogen molecules linking into a network, their gamma-chain ends highlighted. The molecular view is a schematic; exact binding sites are not established.
Fig. 1Illustrative, not to scale. The molecular view is a schematic: the exact binding sites are not established.

×1 Tissue

At the surface, contact.

Ankaferd is applied topically, directly onto the bleeding surface. A protein network forms upon contact with blood in under a second⁠2.

Reportedt < 1 s

×4 Cells

Red cells are drawn together.

The effect is tied to vital erythrocyte aggregation: living red blood cells gather into clusters⁠1.

ReportedProposed: how cells and network interact

×16 Molecules

Fibrinogen gamma, at the centre.

The haemostatic effect is described as depending on the quick promotion of a protein network, particularly fibrinogen gamma, linked to the membrane proteins spectrin, ankyrin and actin of red cells⁠1. Proteomic and transcriptomic analyses have been used to explore these effects⁠3.

ProposedSchematic

Zoom factors describe this illustration, not real magnification.

02 · Cascade-independent

Beside the clotting cascade, not through it.

Ankaferd acts without directly affecting individual coagulation factors⁠1⁠2. Here is what was measured, and what was not.

Fig. 2 The coagulation cascadeSimplified

Simplified coagulation cascade, marking the values reported as normal The intrinsic pathway runs from factor twelve to eleven to nine, with eight as cofactor. The extrinsic pathway runs from tissue factor with factor seven. Both lead to factor ten, then with factor five to prothrombin and thrombin, which turns fibrinogen into fibrin, cross-linked by factor thirteen. Factors five, seven, eight, nine, ten, eleven and thirteen, and the PT and aPTT tests, are marked as reported normal during Ankaferd administration. Factor twelve, tissue factor, prothrombin and fibrinogen are not listed in the cited reviews. aPTT ✓ PT ✓ XII XI IX VIII TF · VII X IIprothrombin V Fibrinogen→ fibrin XIII cross-links fibrinogen γ: see Fig. 1
Reported normal during administration Not listed in the cited reviews

Measured and reported normal⁠1⁠2

Coagulation factors V–XIII, prothrombin time and activated partial thromboplastin time. Hover or focus a value to find it in the diagram.

The Ankaferd route · proposed

  1. Contact with bloodapplied topically to the bleeding surface
  2. Protein networkparticularly fibrinogen gamma, reported in under a second⁠2
  3. Red-cell aggregationvia spectrin, ankyrin and actin⁠1

Why it matters

Because it acts independently of the cascade, Ankaferd has been studied for dental bleeding in people with haemophilia and von Willebrand disease, and in patients taking anticoagulants⁠2⁠32⁠31. These were mostly small studies, and an independent meta-analysis has compared the agents used after extraction⁠31.

Read carefully: normal laboratory values during administration are what was reported. On their own they do not prove that no interaction with coagulation exists.

03 · Levels of evidence

Where the evidence stands.

The evidence base is largely laboratory, animal and small clinical studies, and its own authors call for controlled trials⁠2. Below, the 37 library entries are placed by study design as stated in their titles. Secondary sources and entries whose design we still need to confirm are kept apart.

Fig. 3 Primary studies in this library, placed by the design stated in each title. Each dot is one entry, numbered as in the library; a ringed dot means its bibliographic details are still being confirmed. We have not yet appraised these studies, and the scale describes design, not quality.

  1. Design 1

    Laboratory & animal

    341426: 4 entries: 3, 4, 14 and 26.

    Proteomic and transcriptomic analyses⁠3, a swine bleeding model⁠4, and rat models of alveolar osteitis⁠14 and liver injury⁠26.

  2. Design 2

    Case reports & series

    5132228: 4 entries: 5, 13, 22 and 28; entry 5 has details still to be confirmed.

    A retrospective series of 20 patients with haemoptysis⁠5, and case reports in dental⁠13, diverticular⁠22 and prostatectomy⁠28 bleeding.

  3. Design 3

    Controlled clinical trials

    81011: 3 entries: 8, 10 and 11.

    Tonsillectomy in children⁠8, tooth extraction in haemophilia⁠10 and pulpotomy in primary teeth⁠11.

  4. Design 4

    Randomised trials

    792729: 4 entries: 7, 9, 27 and 29.

    Anterior epistaxis⁠7, adenoid surgery⁠9, tubeless percutaneous nephrolithotomy⁠27 and transradial procedures⁠29.

Across uses, reviewers call for larger controlled trials to confirm clinical benefit⁠2.

Secondary sources

Reviews map the evidence. They are not evidence of a design, so they sit off the scale.

  • 1Çiftçiler & Haznedaroğlu, 2020 · review
  • 2Tibi et al., 2025/26 · narrative review
  • 15Ockerman et al., 2019 · systematic review, dental
  • 16Canellas et al., 2020 · systematic review & network meta-analysis, dental
  • 23Barkun et al., 2013 · systematic review, GI
  • 24Chen & Barkun, 2015 · systematic review, GI

Design to confirm 9

The title does not state the study design, so these are not plotted until we have read the full text.

  • 6Goker et al., 2008 · mechanism
  • 12Beyazit et al., 2011 · dental
  • 17Karaman et al., 2010 · postpolypectomy
  • 18Ozaslan et al., 2010 · non-variceal GI
  • 19Beyazit et al., 2010 · sphincterotomy
  • 20Karaman et al., 2012 · GI bleeding
  • 21Gungor et al., 2012 · non-variceal upper GI
  • 25Ergenoglu et al., 2010 · cardiac surgery
  • 30Öner et al., 2010 · haemophilia with inhibitor

By clinical area

How many primary studies in the library fall in each area, by the design stated in their titles. Trials are controlled or randomised. Secondary reviews are not counted. This is a count, not a systematic review

Number of primary studies in this library for each clinical area, by the study design stated in the title
AreaLaboratoryAnimalCase reportsTrialsTo confirm
Mechanism111
Dental1121
ENT3
GI endoscopy15
Surgery21
Urology11
Cardiology1
Bleeding disorders11
Pulmonology1
Beyond haemostasis

Number of studies listed Investigational: wound healing, antimicrobial, antineoplastic⁠2 None listed

04 · Evidence library

Every source, one click away.

Thirty sources with full citations and DOI or PubMed links. Six we have summarised in one line. The rest come from the manufacturer's published bibliography; they are placed by the design stated in their titles, and we add no summary until we have appraised the full text.

  1. [1]

    Secondary · review · 2020 · Turk J Med Sci

    Çiftçiler R, Haznedaroğlu İC. Ankaferd hemostat: from molecules to medicine. Turk J Med Sci. 2020;50(7):1739–1750. doi:10.3906/sag-1908-161

    In one lineDescribes the fibrinogen-gamma protein network, normal coagulation values during administration, and a negative screen for heavy metals, pesticides, aflatoxins, GMO material and dioxins.

    Secondary source · off the scale

    MechanismSafetyClinical areas

  2. [2]

    Secondary · narrative review · 2025/26 · Ann Med Surg

    Tibi SE, et al. Beyond hemostasis: a narrative review on the multifaceted therapeutic potential of Ankaferd Blood Stopper. Ann Med Surg. 2025/26;88(1):522–533. doi:10.1097/MS9.0000000000004388

    In one lineReports a protein network forming in under a second, flags potential neurotoxicity in rodents, and asks that non-haemostatic uses be treated as investigational.

    Secondary source · off the scale

    Clinical areasSafetyInvestigational uses

  3. [3]

    Laboratory · 2017 · SAGE Open Med

    Simsek C, Selek S, Koca M, Haznedaroglu IC. Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper. SAGE Open Med. 2017;5:2050312117722569. doi:10.1177/2050312117722569

    In one lineProteomic and transcriptomic work exploring the product’s wider effects; it also describes the five-plant composition and summarises an endobronchial haemoptysis series.

    Laboratory · design 1

    MechanismPulmonology

  4. [4]

    Animal model · 2009 · Med Princ Pract

    Bilgili, H., Kosar, A., Kurt, M., Onal, I. K., Goker, H., Captug, O., Shorbagi, A., Turgut, M., Kekilli, M., Kurt, O. K., Kirazli, S., Aksu, S., & Haznedaroglu, I. C. (2009). Hemostatic Efficacy of Ankaferd Blood Stopper in a Swine Bleeding Model. Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre, 18(3), 165–169. doi:10.1159/000204344

    In one lineTests haemostatic efficacy in a swine bleeding model. We have not yet appraised its outcomes, so we do not quote them.

    Animal · design 1

    MechanismSurgery

  5. [5]

    Retrospective clinical · 2014 · n = 20

    Uzun, O., Erkan, L., & Haznedaroglu, I. C. (2014). Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat. Archivos de Bronconeumología, 50(9), 407–409. doi:10.1016/j.arbr.2014.08.001

    In one lineRetrospective series of 20 patients given endobronchial instillation for haemoptysis across 25 bronchoscopies. Small and uncontrolled.

    Case series · design 2

    Pulmonology

  6. [6]

    Design to confirm · 2008 · J Int Med Res

    Goker, H., Haznedaroglu, I. C., Ercetin, S., Kirazli, S., Akman, U., Ozturk, Y., & Firat, H. C. (2008). Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. The Journal of International Medical Research, 36(1), 163–170. doi:10.1177/147323000803600121

    In one lineAn early report on the haemostatic actions of the extract. We will summarise its design and findings once we have appraised the full text.

    Design to confirm

    MechanismDesign to confirm

  7. [7]

    Randomised trial · 2010 · ENT

    Meric Teker, A., Korkut, A. Y., Kahya, V., & Gedikli, O. (2010). Prospective, Randomized, Controlled Clinical Trial of Ankaferd Blood Stopper in Patients with Acute Anterior Epistaxis. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies, 267(9), 1377–1381. doi:10.1007/s00405-010-1208-0

    Randomised · design 4

    ENT

  8. [8]

    Controlled trial · 2009 · ENT

    Teker, A. M., Korkut, A. Y., Gedikli, O., & Kahya, V. (2009). Prospective, Controlled Clinical Trial of Ankaferd Blood Stopper in Children Undergoing Tonsillectomy. International Journal of Pediatric Otorhinolaryngology, 73(12), 1742–1745. doi:10.1016/j.ijporl.2009.09.029

    Controlled · design 3

    ENT

  9. [9]

    Randomised trial · 2018 · ENT

    Abdallah, R. A., Ragab, S. M., & Hassanin, M. Z. (2018). Topical blood stopper agents during adenoid surgery in young children; a prospective randomized controlled trial. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): Affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery, 275(5), 1157–1163. doi:10.1007/s00405-018-4929-0

    Randomised · design 4

    ENT

  10. [10]

    Controlled trial · 2013 · Dental

    Kazancıoğlu, H. O., Cakır, O., Ak, G., & Zülfikar, B. (2013). The Effectiveness of a New Hemostatic Agent (Ankaferd Blood Stopper) for the Control of Bleeding following Tooth Extraction in Hemophilia: A Controlled Clinical Trial. Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology, 30(1), 19–24. doi:10.4274/tjh.2012.0036

    Controlled · design 3

    DentalBleeding disorders

  11. [11]

    Controlled trial · 2017 · Dental

    Ozmen, B., & Bayrak, S. (2017). Comparative evaluation of ankaferd blood stopper, ferric sulfate, and formocresol as pulpotomy agent in primary teeth: A clinical study. Nigerian Journal of Clinical Practice, 20(7), 832–838. doi:10.4103/1119-3077.197022

    Controlled · design 3

    Dental

  12. [12]

    Design to confirm · 2011 · Dental

    Beyazit, Y., Kart, T., Kuscu, A., Arslan, A., Kurt, M., Aktas, B., Kekilli, M., & Haznedaroglu, I. (2011). Successful Management of Bleeding after Dental Procedures with Application of Blood Stopper: A Single Center Prospective Trial. The Journal of Contemporary Dental Practice, 12(5), 379–384. PubMed 22269200

    Design to confirm

    Dental

  13. [13]

    Case report · 2009 · Dental

    Koray, M., Ergun, S., Saruhanoglu, A., & Tanyeri, H. (2009). Use of a new local haemostatic agent Ankaferd blood stopper after surgical excision of eruption cyst: A case report. International Journal of Oral and Maxillofacial Surgery, 38(5), 558. doi:10.1016/j.ijom.2009.03.563

    Case report · design 2

    Dental

  14. [14]

    Animal study · 2021 · Dental

    Burdurlu, M. Ç., Cabbar, F., Dagasan, V. Ç., Işıksaçan, N. S., & Olgaç, V. (2021). The preventive effect of medicinal herbal extract and gelatin sponge on alveolar osteitis: An in vivo micro-computed tomography and immunohistochemical analysis in rats. Archives of Oral Biology, 122, 105002. PubMed 33316659

    Animal · design 1

    Dental

  15. [15]

    Secondary · systematic review · 2019 · Dental

    Ockerman, A., Miclotte, I., Vanhaverbeke, M., Verhamme, P., Poortmans, L.-L., Vanassche, T., Politis, C., & Jacobs, R. (2019). Local haemostatic measures after tooth removal in patients on antithrombotic therapy: A systematic review. Clinical Oral Investigations, 23(4), 1695–1708. doi:10.1007/s00784-018-2576-x

    Secondary source · off the scale

    Dental

  16. [16]

    Secondary · systematic review · 2020 · Dental

    Canellas, J. V. dos S., Fraga, S. R. G., Santoro, M. F., Netto, J. de N. S., & Tinoco, E. M. B. (2020). Intrasocket interventions to prevent alveolar osteitis after mandibular third molar surgery: A systematic review and network meta-analysis. Journal of Cranio-Maxillofacial Surgery, 48(9), 902–913. doi:10.1016/j.jcms.2020.06.012

    Secondary source · off the scale

    Dental

  17. [17]

    Design to confirm · 2010 · GI endoscopy

    Karaman, A., Torun, E., Gürsoy, S., Yurci, A., & Ozbakir, O. (2010). Efficacy of Ankaferd Blood Stopper in Postpolypectomy Bleeding. Journal of Alternative and Complementary Medicine, 16(10), 1027–1028. doi:10.1089/acm.2010.0089

    Design to confirm

    GI endoscopy

  18. [18]

    Design to confirm · 2010 · GI endoscopy

    Ozaslan, E., Purnak, T., Yildiz, A., & Haznedaroglu, I. C. (2010). The Effect of a New Hemostatic Agent for Difficult Cases of Non-Variceal Gastrointestinal Bleeding: Ankaferd Blood Stopper. Hepato-Gastroenterology, 57(98), 191–194. PubMed 20583410

    Design to confirm

    GI endoscopy

  19. [19]

    Design to confirm · 2010 · GI endoscopy

    Beyazit, Y., Köklü, S., Akbal, E., Kurt, M., Kekilli, M., & Haznedaroglu, I. C. (2010). Successful Treatment of Endoscopic Sphincterotomy-Induced Early Hemorrhage with Application of Ankaferd Blood Stopper. Gastrointestinal Endoscopy, 72(6), 1325–1326. doi:10.1016/j.gie.2010.03.1119

    Design to confirm

    GI endoscopy

  20. [20]

    Design to confirm · 2012 · GI endoscopy

    Karaman, A., Baskol, M., Gursoy, S., Torun, E., Yurci, A., Celikbilek, M., Guven, K., Ozbakir, O., & Yucesoy, M. (2012). Endoscopic Topical Application of Ankaferd Blood Stopper® in Gastrointestinal Bleeding. Journal of Alternative and Complementary Medicine, 18(1), 65–68. doi:10.1089/acm.2010.0827

    Design to confirm

    GI endoscopy

  21. [21]

    Design to confirm · 2012 · GI endoscopy

    Gungor, G., Goktepe, M. H., Biyik, M., Polat, I., Tuna, T., Ataseven, H., & Demir, A. (2012). Efficacy of ankaferd blood stopper application on non-variceal upper gastrointestinal bleeding. World Journal of Gastrointestinal Endoscopy, 4(12), 556–560. doi:10.4253/wjge.v4.i12.556

    Design to confirm

    GI endoscopy

  22. [22]

    Case report · 2013 · GI endoscopy

    Aslan, E., Akyüz, Ü., & Pata, C. (2013). The use of Ankaferd in diverticular bleeding: Two case reports. The Turkish Journal of Gastroenterology: The Official Journal of Turkish Society of Gastroenterology, 24(5), 441–443. doi:10.4318/tjg.2013.0640

    Case report · design 2

    GI endoscopy

  23. [23]

    Secondary · systematic review · 2013 · GI endoscopy

    Barkun, A. N., Moosavi, S., & Martel, M. (2013). Topical hemostatic agents: A systematic review with particular emphasis on endoscopic application in GI bleeding. Gastrointestinal Endoscopy, 77(5), 692–700. doi:10.1016/j.gie.2013.01.020

    Secondary source · off the scale

    GI endoscopy

  24. [24]

    Secondary · systematic review · 2015 · GI endoscopy

    Chen, Y.-I., & Barkun, A. N. (2015). Hemostatic Powders in Gastrointestinal Bleeding: A Systematic Review. Gastrointestinal Endoscopy Clinics of North America, 25(3), 535–552. doi:10.1016/j.giec.2015.02.008

    Secondary source · off the scale

    GI endoscopy

  25. [25]

    Design to confirm · 2010 · Surgery

    Ergenoglu, M. U., Yerebakan, H., & Kucukaksu, D. S. (2010). A New Practical Alternative for the Control of Sternal Bleeding during Cardiac Surgery: Ankaferd Blood Stopper. The Heart Surgery Forum, 13(6), E379-380. doi:10.1532/HSF98.20101071

    Design to confirm

    Surgery

  26. [26]

    Animal study · 2021 · Surgery

    Ergin, M., & Özer, N. (2021). Comparison of hemostatic efficacy of topical Ankaferd Blood Stopper on heparinized and nonheparinized rats in bleeding related to liver injury. Acta Cirurgica Brasileira, 36(1), e360106. doi:10.1590/ACB360106

    Animal · design 1

    Surgery

  27. [27]

    Randomised trial · 2013 · Urology

    Istanbulluoğlu, M. O., Kaynar, M., Ciçek, T., Koşan, M., Oztürk, B., & Ozkardeş, H. (2013). A new hemostatic agent (ankaferd blood stopper(®)) in tubeless percutaneous nephrolithotomy: A prospective randomized study. Journal of Endourology / Endourological Society, 27(9), 1126–1130. doi:10.1089/end.2013.0086

    Randomised · design 4

    Urology

  28. [28]

    Case report · 2009 · Urology

    Huri, E., Akgül, T., Ayyildiz, A., & Germiyanoğlu, C. (2009). Hemostasis in Retropubic Radical Prostatectomy with Ankaferd BloodStopper: A Case Report. The Kaohsiung Journal of Medical Sciences, 25(8), 445–447. PubMed 19605339

    Case report · design 2

    Urology

  29. [29]

    Randomised trial · 2018 · Cardiology

    Gorgulu, S., Norgaz, T., & Sipahi, I. (2018). Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: A randomized clinical trial. Journal of Interventional Cardiology, 31(4), 511–517. PubMed 29667233

    Randomised · design 4

    Cardiology

  30. [30]

    Design to confirm · 2010 · Bleeding disorders

    Öner, A. F., Doğan, M., Kaya, A., Sal, E., Bektaş, M. S., Yesilmen, O., Ayhan, H., & Acikgoz, M. (2010). New Coagulant Agent (Ankaferd Blood Stopper) for Open Hemorrhages in Hemophilia with Inhibitor. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 16(6), 705–707. doi:10.1177/1076029609337313

    Design to confirm

    Bleeding disorders

  31. [31]

    Network meta-analysis · 2023 · Sci Rep

    Mahardawi, B., Jiaranuchart, S., Arunjaroensuk, S., Tompkins, K. A., Somboonsavatdee, A., & Pimkhaokham, A. (2023). The effect of different hemostatic agents following dental extraction in patients under oral antithrombotic therapy: a network meta-analysis. Scientific Reports, 13(1), 12519. doi:10.1038/s41598-023-39023-7

    In one lineAn independent network meta-analysis comparing haemostatic agents after tooth extraction in patients on antithrombotic therapy; Ankaferd is among the agents compared.

    Meta-analysis · design 5

    DentistrySecondary source

  32. [32]

    Controlled clinical · 2013 · Clin Appl Thromb Hemost

    Çakarer, S., Eyüpoğlu, E., Özçamur Güneş, Ç., Küseoğlu, B. G., Koçak Berberoğlu, H., & Keskin, C. (2013). Evaluation of the Hemostatic Effects of Ankaferd Blood Stopper During Dental Extractions in Patients on Antithrombotic Therapy. Clinical and Applied Thrombosis/Hemostasis. 2013. doi:10.1177/1076029611435836 · PubMed 22327817

    In one lineA clinical study of Ankaferd for bleeding control during tooth extraction in patients on antithrombotic therapy.

    Controlled · design 3

    DentistryAnticoagulation

  33. [33]

    Animal model · 2024 · Exp Ther Med

    Üstün, R., Oğuz, E. K., Şeker, A., & Taspinar, F. (2024). Functional and structural neurodegenerative activities of Ankaferd BloodStopper in a mouse sciatic nerve model. Experimental and Therapeutic Medicine, 28(3), 345. doi:10.3892/etm.2024.12634

    In one lineIn a mouse sciatic-nerve model, direct application was associated with functional and structural nerve damage; the authors conclude it is neurotoxic in this model and call for further study. Supports the caution against direct contact with exposed nerves.

    Animal · design 1

    SafetyNeural tissue

  34. [34]

    Randomised · 2013 · Clin Exp Obstet Gynecol

    Yapar Eyi, E. G., Engin-Üstün, Y., Kaba, M., & Mollamahmutoğlu, L. (2013). Ankaferd blood stopper in episiotomy repair. Clinical and Experimental Obstetrics & Gynecology, 40(1), 141–143. PubMed 23724529

    In one lineA small randomised comparison (20 vs 20) of Ankaferd spray against saline for blood loss during episiotomy repair.

    Randomised · design 4

    Obstetrics

  35. [35]

    Clinical · 2019 · Adv Ther

    Koyuncu, N. (2019). The Effectiveness of Ankaferd Blood Stopper in the Management of Traumatic Bleeding. Advances in Therapy, 36(5), 1143–1149. doi:10.1007/s12325-019-00935-4

    In one lineA clinical report on Ankaferd for traumatic external bleeding in the emergency setting.

    Clinical · design 2

    EmergencyTrauma

  36. [36]

    Clinical · 2018 · Turk J Haematol

    Patıroğlu, T., Erdoğ Şahin, N., Ünal, E., Kendirci, M., Karakükcü, M., & Özdemir, M. A. (2018). Effectiveness of Ankaferd BloodStopper in Prophylaxis and Treatment of Oral Mucositis in Childhood Cancers Evaluated with Plasma Citrulline Levels. Turkish Journal of Haematology, 35(1), 85–86. doi:10.4274/tjh.2017.0320

    In one lineEvaluates Ankaferd for oral mucositis in children with cancer, using plasma citrulline as a marker. An investigational, non-haemostatic use.

    Clinical · design 2

    Paediatric oncologyInvestigational

  37. [37]

    Clinical · 2014 · Niger J Clin Pract

    Tek, M., Akkas, I., Toptas, O., Ozan, F., Sener, I., & Bereket, C. (2014). Effects of the topical hemostatic agent Ankaferd Blood Stopper on the incidence of alveolar osteitis after surgical removal of an impacted mandibular third molar. Nigerian Journal of Clinical Practice, 17(1), 75. doi:10.4103/1119-3077.122847

    In one lineExamines whether Ankaferd affects the incidence of dry socket after removal of an impacted lower wisdom tooth.

    Clinical · design 3

    Oral surgery

Evidence-level bars are an editorial guide to study design, not a quality score. Designs for entries 7–30 are taken from their titles; we have not yet appraised them. Summaries are ours; read the source before relying on any finding.

05 · Safety profile

Safety, candidly.

What has been tested, what is still debated, and what we ask of everyone who uses it.

Nerve cross-section with a no-direct-contact zone A cross-section of a peripheral nerve with bundles of nerve fibres, surrounded by a dashed ring marking a zone where Ankaferd should not be applied directly. A drop of solution outside the ring is shown stopping at the boundary. NO DIRECT CONTACT FASCICLE EPINEURIUM
Fig. 4Exposed neural tissue: avoid direct application. Illustrative.

The neurotoxicity question

Reported
Biocompatible in most studies⁠2
Open
Potential neurotoxicity seen in rodents⁠2⁠33
After direct nerve exposure: neurotoxic potential is debated⁠2⁠33

Pending the IFU wording, we advise cautionAvoid applying Ankaferd directly onto exposed neural tissue. IFU wording to be confirmed.

Contaminant screen

Reported as tested negative⁠1
AnalyteResult
Heavy metals lead, cadmium, mercury, arsenicNegative
PesticidesNegative
AflatoxinsNegative
GMO materialNegative
DioxinsNegative

A clean contaminant screen speaks to purity. On its own it is not evidence of clinical safety.

Follow the Instructions for UseThe IFU, not this website, is the reference for indications, contraindications, warnings, application and storage.

  • IndicationsTopical control of external bleeding — wounds and traumatic incisions; may be used across patient groups, including people with haemophilia, diabetes or high blood pressure (per the IFU).
  • ContraindicationsNone known (per the IFU).
  • Warnings & precautionsSingle-use and sterile. Not to be placed into a vein or the bloodstream. If bleeding has not stopped after five minutes, use a new tampon; if it still does not stop, use another method and seek medical care (per the IFU).
  • Storage & shelf lifeStore at 0–25 °C, protected from sunlight; do not use if the packaging is damaged. Shelf life 4 years (per the IFU).

Download the Instructions for Use (PDF, in German and English)

Beyond bleeding

Wound-healing, antimicrobial and antineoplastic effects have been described. They must be regarded as investigational⁠2, and this site makes no claim for them.

Report a suspected adverse event

Contact sicherheit@ankaferd.info. In Germany, suspected incidents with medical devices can also be reported to the BfArM, the competent authority for medical devices.

06 · Open questions

What would make the evidence stronger.

We list the gaps because clinicians deserve to see them. If you are running a study, or know one we have missed, we would like to hear from you.

Share a study with us See clinical applications

  1. Larger controlled trials

    Reviewers call for controlled studies to confirm clinical benefit⁠2.

  2. Neural tissue

    Neurotoxic potential after direct nerve exposure remains debated⁠2.

  3. The molecular detail

    The mechanism is proposed. Exactly how the network binds is not yet established.

  4. Uses beyond bleeding

    Wound healing, antimicrobial and antineoplastic effects remain investigational⁠2.

  5. Status outside Türkiye

    In the EU it is a CE-marked medical device (Class III, Directive 93/42/EEC, notified body TSE) for the topical control of external bleeding, distributed in Germany. It is approved by the Turkish Ministry of Health for dental and superficial bleeding⁠2. Status in other regions is still being confirmed.